| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/14/2006 | US7012100 Cell migration inhibiting compositions and methods and compositions for treating cancer |
| 03/14/2006 | US7012099 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 03/14/2006 | US7012098 Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
| 03/14/2006 | US7012097 Anticancer agents based on prevention of protein prenylation |
| 03/14/2006 | US7012096 Comprising a weak organic acid such as acetic acid, vinegar, and/or citric acid dispersed within a carrier, at acidic pH, for treating burns; provides local analgesia |
| 03/14/2006 | US7012095 Compounds for modulating cell proliferation |
| 03/14/2006 | US7012094 such as 3-(4-fluorophenyl)-4-(methylsulfonylphenyl)furan; for treatment of arthritis |
| 03/14/2006 | US7012093 Multiple fluorescent natural dye compound from a marine organism and method of use thereof |
| 03/14/2006 | US7012091 oral/nasal administration of sesquiterpene epoxide compounds (trichothecenes) to attenuate hyperactive protein synthesis by mast cells or other secretory cells |
| 03/14/2006 | US7012090 Pyranoindoles for treating glaucoma |
| 03/14/2006 | US7012089 Administering to a patient suffering from psychological disoders a (1,4)diazocino(7,7,1-hi)inodle derivative as 5HT2c agonist or partial agonist |
| 03/14/2006 | US7012088 Indolone oxazolidinones and derivatives thereof |
| 03/14/2006 | US7012087 Anticancer agents |
| 03/14/2006 | US7012086 Treatment of retrovirus induced derangements with niacin compounds |
| 03/14/2006 | US7012085 As antipsychotics in therapy of schizophrenia, depression, bipolar disorders, cognition deficits, Parkinson disease, drug abuse, attention deficit hyperactivity disorders, glaucoma, diabetes and erectile dysfunction |
| 03/14/2006 | US7012084 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 03/14/2006 | US7012083 For prophylaxis and therapy of pruritus |
| 03/14/2006 | US7012082 Method of correcting HERG channel dysfunction |
| 03/14/2006 | US7012081 Antiproliferative agents; skin disorders; vision defects; liver and kidney disorders |
| 03/14/2006 | US7012080 Imidazopyridine compounds as 5-HT4 receptor agonists |
| 03/14/2006 | US7012079 (5R)-5-ethyl-9,10,difluoro-5-hydroxy-12-(2-trimethylsilylethyl)-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]-indoloizino[1,2-b]quinoline-3,15-dione for treatment of colon cancer |
| 03/14/2006 | US7012078 For therapy and prophylaxis of migraine, inflammatory diseases, stroke, acute and chronic pain, hypovolemic shock, traumatic shock, reperfusion injury, Crohn's disease, ulcerative colitis, septic shock, multiple sclerosis, etc. |
| 03/14/2006 | US7012077 Anticholesterol agents; antilipemic agents |
| 03/14/2006 | US7012076 Quinazoline-4-sulfonamide derivatives |
| 03/14/2006 | US7012075 Cathepsin cysteine protease inhibitors |
| 03/14/2006 | US7012074 Use in particular atrial and ventricular arrhythmias; e.g. 1-cyano-1-methylethyl 8-(2-amino-4-(4-cyanophenoxy)butyl)-3,8-diazabicyclo(3.2.1)octane-3-carboxylate |
| 03/14/2006 | US7012073 Quinoline derivatives |
| 03/14/2006 | US7012072 Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same |
| 03/14/2006 | US7012071 such as 4-(4-(2-Fluorobenzyloxy)phenyl)-4-oxobutyric acid; for treatment of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis |
| 03/14/2006 | US7012070 Estrogenic compounds as anti-mitotic agents |
| 03/14/2006 | US7012069 For therapy of heart disease and stroke, Alzheimer's disease, and an inflammatory disorder |
| 03/14/2006 | US7012068 Reduced toxicity; enhance efficiency; side effect reduction |
| 03/14/2006 | US7012067 Synergistic mixture containing simvastatin |
| 03/14/2006 | US7012066 for coadministration with interferon and antiviral agent |
| 03/14/2006 | US7012063 Reducing axon degeneration with proteasome inhibitors |
| 03/14/2006 | US7012060 administering to patient a TNF receptor, the improvement wherein TNF receptor is administered with dehydroepiandrosterone simultaneously, separately or sequentially, so as to achieve an effective blood level of the combination |
| 03/14/2006 | US7011973 recombinant DNA molecules comprising regulatory sequences of an intron of the Vascular Endothelial Growth Factor receptor-2 gene or of a gene homologous to the Flk-1 gene, being capable of conferring expression of a heterologous DNA sequence |
| 03/14/2006 | US7011962 Method of producing lipids by growing microorganisms of the order thraustochyriales |
| 03/14/2006 | US7011855 Biochemically balanced peritoneal dialysis solutions |
| 03/14/2006 | US7011854 Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof |
| 03/14/2006 | US7011851 Drug delivery; incontinence therapy |
| 03/14/2006 | US7011848 Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| 03/14/2006 | US7011847 Enteric coated formulation for bisphosphonic acids and salts thereof |
| 03/14/2006 | US7011844 Formulations for the administration of fluoxetine |
| 03/14/2006 | US7011839 Combination of an antimicrobial, especially a quinolone antibiotic, and silver sulfadiazine |
| 03/14/2006 | US7011826 Control of acidosis |
| 03/14/2006 | US7011822 Effective soft solid personal care product |
| 03/14/2006 | US7011820 Delivery of compounds for the treatment of Parkinsons through an inhalation route |
| 03/14/2006 | US7011819 Increasing the rate at which the peak plasma concentrations are reached by delivering the drug in a single inspiration from a dispenser in which the condensation aerosol was formed by cooling a vapor formed by heating a thin layer on a support; less than 10% degradation products and a mass median aerosol |
| 03/14/2006 | US7011818 Promotes the release of the active particles from the carrier particles on actuation of the inhaler; efficiency |
| 03/14/2006 | US7011816 Complex of gallium-68 with a macrocyclic chelating agent linked via peptidyl spacer to one or more recognition units recognized by a multispecific targeting antibody |
| 03/14/2006 | US7011093 Nasal dilators and strips, methods of their manufacture, and methods for improving the breathing of individuals are provided. The strips and dilators include an elongated substrate, with or without a dilating component or portion, |
| 03/14/2006 | CA2584412A1 Methods for diagnosis and treatment of cancer |
| 03/14/2006 | CA2521953C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 03/14/2006 | CA2380810C Pyridomorphinans and use thereof |
| 03/14/2006 | CA2376748C Diphosphate salt of a 4''-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition |
| 03/14/2006 | CA2376091C Ethanesulfonyl-piperidine derivatives |
| 03/14/2006 | CA2375430C C-pyrazole a2a receptor agonists |
| 03/14/2006 | CA2359363C 4-(heterocyclylsulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists |
| 03/14/2006 | CA2357687C New pyridazine endothelin antagonists |
| 03/14/2006 | CA2312935C Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors |
| 03/14/2006 | CA2312710C Sustained release formulation containing three different types of polymers and tablet formed therefrom |
| 03/14/2006 | CA2308867C New substitute pyridine or piperidine compounds, their preparation process and the pharmaceutical compositions containing these compounds |
| 03/14/2006 | CA2297825C Indole and 2,3-dihydroindole derivatives, their preparation and use |
| 03/14/2006 | CA2295515C Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof |
| 03/14/2006 | CA2289987C Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia |
| 03/14/2006 | CA2278241C Phenyl heterocycles as cyclooxygenase-2 inhibitors |
| 03/14/2006 | CA2269531C Substituted benzoylaminothiazole derivatives and drugs containing the same |
| 03/14/2006 | CA2268796C Bi-aromatic compounds bound by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing same |
| 03/14/2006 | CA2267879C Heteroaryl succinamides and their use as metalloproteinase inhibitors |
| 03/14/2006 | CA2250731C In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue |
| 03/14/2006 | CA2241014C Morphine derivatives with analgesic activity |
| 03/14/2006 | CA2239547C Benzazepine derivatives with vasopressin agonistic activity |
| 03/14/2006 | CA2237005C Quinazoline derivatives |
| 03/14/2006 | CA2214070C Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods |
| 03/14/2006 | CA2210631C Tricyclic benzazepine vasopressin antagonists |
| 03/14/2006 | CA2206333C Novel anthracycline compound derivative and pharmaceutical preparation containing the same |
| 03/14/2006 | CA2176557C Phenyl-alkyl imidazoles as h3-receptor antagonists |
| 03/14/2006 | CA2165800C Antiallergic imidazoazepines |
| 03/14/2006 | CA2147984C Butenyl-substituted taxanes and composition |
| 03/14/2006 | CA2127166C Sustained release morphine compositions and a method of preparation |
| 03/14/2006 | CA2103838C Novel 7-(substituted)-8-(substituted-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines |
| 03/14/2006 | CA2051494C 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors |
| 03/09/2006 | WO2006026760A2 1-amino imidazo-containing compounds and methods |
| 03/09/2006 | WO2006026747A2 Diphenylethylene compounds and uses thereof |
| 03/09/2006 | WO2006026663A1 Methods for treating congestive heart failure |
| 03/09/2006 | WO2006026619A2 Inhibition of viruses using rnase h inhibitors |
| 03/09/2006 | WO2006026597A2 Novel compositions and methods of treatment |
| 03/09/2006 | WO2006026555A2 Neuroprotective effect of solubilized udca in focal ischemic model |
| 03/09/2006 | WO2006026536A2 Method of treatment of cancer using guanosine 3’, 5’ cyclic monophosphate (cyclic gmp) |
| 03/09/2006 | WO2006026533A2 Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors |
| 03/09/2006 | WO2006026524A2 Werner's syndrome helicase as a target for anti-hiv/aids therapy |
| 03/09/2006 | WO2006026502A1 Enhanced delivery of drug compositions to treat life threatening infections |
| 03/09/2006 | WO2006026500A1 New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders |
| 03/09/2006 | WO2006026470A2 Hiv immunostimulatory compositions |
| 03/09/2006 | WO2006026469A2 Pharmaceutical formulations of potassium atp channel openers and uses thereof |
| 03/09/2006 | WO2006026458A2 Compositions and methods for activating protein synthesis and deactivating catabolic processes in skeletal muscle |
| 03/09/2006 | WO2006026430A2 Cyclopamine analogues and methods of use thereof |
| 03/09/2006 | WO2006026395A1 Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof |
| 03/09/2006 | WO2006026394A2 Method of eliciting an immune response against hiv |